Sugi Predict

Sugi Predict / Targets / CEP170

CEP170

Centrosomal protein of 170 kDa · Q5SW79 · CEP170 on Sugi Atlas →

0 patent compounds predicted against CEP170, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to CEP170 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Management of Retinitis Pigmentosa Via Combination of Wharton's Jelly-derived Mesenchymal Stem Cells and Magnovision PHASE3COMPLETED
Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety PHASE2COMPLETED
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL PHASE1/PHASE2RECRUITING
Peptide Vaccine Focusing on Prevention of the Recurrence for Bladder Cancer PHASE2UNKNOWN
Phase I/II Safety Study of IPI-504 in Relapsed/Refractory Stage IIIb, or Stage IV Non-small Cell Lung Cancer (NSCLC) PHASE1/PHASE2COMPLETED
Study of ABT-751 in Patients With Refractory Hematologic Malignancies PHASE1COMPLETED
Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel PHASE1COMPLETED
Phase I Study to Assess the Safety, Pharmacokinetics, & Pharmacodynamics of GSK923295 in Subjects w/ Refractory Cancer PHASE1COMPLETED
Novel Peptide Vaccination for Patients With Advanced Bladder Cancer PHASE1COMPLETED
Functional Studies of Novel Genes Mutated in Primary Ciliary Dyskinesia II: Genotype to Phenotype EARLY_PHASE1COMPLETED
Classification, Functional Stratification and Biomarkers in Ciliopathy (CILLICORIRCM) nanCOMPLETED
PCM1-JAK2 in Therapy Related Neoplasms nanUNKNOWN
PCD New Gene Discovery nanCOMPLETED
Importance of the Microtubule Cytoskeleton in Oocyte Competence nanCOMPLETED
Genetic Study of Patients With Primary Ciliary Dyskinesia nanCOMPLETED
Pathogenesis of Primary Ciliary Dyskinesia (PCD) Lung Disease nanRECRUITING
iPSC Neurons From Adult Survivors of Childhood Cancer Who Have Persistent Vincristine-Induced Neuropathy nanCOMPLETED
Research of Therapeutic Targets in the Frame of Nephronophthisis and Renal Associated Ciliopathies nanRECRUITING
Natural History Study of CEP290-Related Retinal Degeneration nanCOMPLETED
Genetics of Primary Ciliary Dyskinesia nanCOMPLETED
Primary Ciliary Dyskinesia in Adult Bronchiectasis nanNOT_YET_RECRUITING
Amplification of Zinc Finger Protein 217 Gene in Multiple Myeloma nanUNKNOWN
Characterization of New Candidate Genes in Cases of Human Inherited Thrombocytopenia (CATCH) nanCOMPLETED
Diagnosis of Primary Ciliary Dyskinesia nanCOMPLETED
Mapping Disease Pathways for Biliary Atresia nanRECRUITING
Chromosome 9 P Minus Syndrome nanRECRUITING
NGS Panel of Incomplete Forms of Ocular Albinism nanCOMPLETED
Whole Genome Scan of Extended Families With Familial Vocal Cord Paralysis nanCOMPLETED
Collaborative Studies on the Genetics of Asthma (CSGA) nanCOMPLETED
Genetics and Psychopathology in the 22q11 Deletion Syndrome nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a CEP170 binder may also engage these)

ProteinNameSimilarity
Q6A065 — 1.000 Q6A065 →
Q498L0 — 1.000 Q498L0 →
PEAK1 Inactive tyrosine-protein kinase PEAK1 0.998 landscape →
A6QP06 — 0.997 A6QP06 →
A0JM08 — 0.997 A0JM08 →
A6H5Y1 — 0.997 A6H5Y1 →
Q5VT06 — 0.996 Q5VT06 →
Q2PFD7 — 0.995 Q2PFD7 →
A2RUV4 — 0.995 A2RUV4 →
A2AHC3 — 0.995 A2AHC3 →
Q811D2 — 0.995 Q811D2 →
Q96JQ2 — 0.995 Q96JQ2 →
A0A1L8HFX9 — 0.995 A0A1L8HFX9 →
Q9P1A6 — 0.995 Q9P1A6 →
Q8C5W0 — 0.995 Q8C5W0 →
F1QIC4 — 0.995 F1QIC4 →
Q9Y7S8 — 0.994 Q9Y7S8 →
A2ARZ3 — 0.994 A2ARZ3 →
Q8IVL0 — 0.994 Q8IVL0 →
Q66J90 — 0.994 Q66J90 →
Q9HCH5 — 0.994 Q9HCH5 →
Q80TN7 — 0.994 Q80TN7 →
P10244 — 0.994 P10244 →
Q6DFV3 — 0.994 Q6DFV3 →
Q27IV2 — 0.994 Q27IV2 →
Q8IZ21 — 0.994 Q8IZ21 →
E9Q309 — 0.994 E9Q309 →
Q15154 — 0.993 Q15154 →
O60284 — 0.993 O60284 →
Q5TZ18 — 0.993 Q5TZ18 →